Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.

导出 LinkOut

翻译打印收藏纠错

作者： E,Borazanci ^[1] ; A M,Schram ^[2] ; E,Garralda ^[3] ; I,Brana ^[3] ; M,Vieito Villar ^[3] ; A,Spreafico ^[4] ; M,Oliva ^[4] ; N J,Lakhani ^[5] ; K,Hoffman ^[6] ; R M,Hallett ^[6] ; D,Maetzel ^[6] ; F,Hua ^[7] ; J,Hilbert ^[7] ; P,Giblin ^[6] ; J,Anido ^[6] ; A,Kelly ^[6] ; P J,Vickers ^[6] ; R,Wasserman ^[6] ; J,Seoane ^[8] ; L L,Siu ^[4] ; D M,Hyman ^[2] ; D V,Hoff ^[9] ; J,Tabernero ^[10]

作者单位： HonorHealth, Scottsdale, USA. Electronic address: eborazanci@honorhealth.com. ^[1] Memorial Sloan Kettering Cancer Center, New York, USA. ^[2] Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain. ^[3] Princess Margaret Cancer Centre, Toronto, Canada. ^[4] START Midwest, Grand Rapids, USA. ^[5] Northern Biologics, Inc., Toronto, Canada. ^[6] Applied BioMath, Concord, USA. ^[7] Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Universitat Autònoma de Barcelona (UAB), CIBERONC, Barcelona. ^[8] HonorHealth, Scottsdale, USA. ^[9] Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain. ^[10]

关键词 STAT3 leukemia inhibitory factor monoclonal antibody safety solid tumors

主题词抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);人类(Humans);最大耐受剂量(Maximum Tolerated Dose);肿瘤(Neoplasms);肿瘤微环境(Tumor Microenvironment)

DOI 10.1016/j.esmoop.2022.100530

PMID 35921760

发布时间 2022-11-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

ESMO open

2022年7卷4期

100530页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.

ESMO open

相似文献

ESMO open

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.

ESMO open

相似文献

ESMO open

相关期刊

检索历史清除